|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Senosain MF and Massion PP: Intratumor
heterogeneity in early lung adenocarcinoma. Front Oncol.
10:3492020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JM and Chen DS: Immune escape to
PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann
Oncol. 27:1492–1504. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goldberg SB, Gettinger SN, Mahajan A,
Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A,
Jilaveanu L, et al: Pembrolizumab for patients with melanoma or
non-small-cell lung cancer and untreated brain metastases: Early
analysis of a non-randomised, open-label, phase 2 trial. Lancet
Oncol. 17:976–983. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cohen EEW, Soulières D, Le Tourneau C,
Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R,
et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab
for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bauml J, Seiwert TY, Pfister DG, Worden F,
Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, et al:
Pembrolizumab for platinum-and cetuximab-refractory head and neck
cancer: Results from a single-arm, phase II study. J Clin Oncol.
35:1542–1549. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Powles T, Durán I, van der Heijden MS,
Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano
D, Bamias A, et al: Atezolizumab versus chemotherapy in patients
with platinum-treated locally advanced or metastatic urothelial
carcinoma (IMvigor211): A multicentre, open-label, phase 3
randomised controlled trial. Lancet. 391:748–757. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Overman MJ, Lonardi S, Wong KY, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Velcheti V, Schalper KA, Carvajal DE,
Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L
and Rimm DL: Programmed death ligand-1 expression in non-small cell
lung cancer. Lab Invest. 94:107–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+
T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci USA. 104:3360–3365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vito A, El-Sayes N and Mossman K:
Hypoxia-driven immune escape in the tumor microenvironment. Cells.
9:9922020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang X, Wang J, Deng X, Xiong F, Ge J,
Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor
microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol
Cancer. 18:102019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
You L, Wu W, Wang X, Fang L, Adam V,
Nepovimova E, Wu Q and Kuca K: The role of hypoxia-inducible factor
1 in tumor immune evasion. Med Res Rev. 41:1622–1643. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pfoh R, Lacdao IK and Saridakis V:
Deubiquitinases and the new therapeutic opportunities offered to
cancer. Endocr Relat Cancer. 22:T35–T54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Melo-Cardenas J, Zhang Y, Zhang DD and
Fang D: Ubiquitin-specific peptidase 22 functions and its
involvement in disease. Oncotarget. 7:44848–44856. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang K, Yang L, Wang J, Sun T, Guo Y,
Nelson R, Tong TR, Pangeni R, Salgia R and Raz DJ:
Ubiquitin-specific protease 22 is critical to in vivo angiogenesis,
growth and metastasis of non-small cell lung cancer. Cell Commun
Signal. 17:1672019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang X, Zhang Q, Lou Y, Wang J, Zhao X,
Wang L, Zhang X, Li S, Zhao Y, Chen Q, et al: USP22 Deubiquitinates
CD274 to suppress anticancer immunity. Cancer Immunol Res.
7:1580–1590. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sunshine J and Taube JM: PD-1/PD-L1
inhibitors. Curr Opin Pharmacol. 23:32–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Santos RM, Moreno C and Zhang WC:
Non-Coding RNAs in lung tumor initiation and progression. Int J Mol
Sci. 21:27742020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen J, Jiang CC, Jin L and Zhang XD:
Regulation of PD-L1: A novel role of pro-survival signalling in
cancer. Ann Oncol. 27:409–416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi
S, Hanley SJ, Yue J, Watari H and Sakuragi N: Control of PD-L1
expression by miR-140/142/340/383 and oncogenic activation of the
OCT4-miR-18a pathway in cervical cancer. Oncogene. 37:5257–5268.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang S, Miao D, Wang M, Lv J, Wang Y and
Tong J: miR-30-5p suppresses cell chemoresistance and stemness in
colorectal cancer through USP 22/Wnt/β-catenin signaling axis. J
Cell Mol Med. 23:630–640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D,
Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p
functions as a tumor suppressor and novel therapeutic tool by
targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res.
74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun X, Li CW, Wang WJ, Chen MK, Li H, Lai
YJ, Hsu JL, Koller PB, Chan LC, Lee PC, et al: Inhibition of c-MET
upregulates PD-L1 expression in lung adenocarcinoma. Am J Cancer
Res. 10:564–571. 2020.PubMed/NCBI
|
|
33
|
Avendaño-Ortiz J, Maroun-Eid C,
Martín-Quirós A, Toledano V, Cubillos-Zapata C, Gómez-Campelo P,
Varela-Serrano A, Casas-Martin J, Llanos-González E, Alvarez E, et
al: PD-L1 overexpression during endotoxin tolerance impairs the
adaptive immune response in septic patients via HIF1α. J Infect
Dis. 217:393–404. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin YH: MicroRNA networks modulate
oxidative stress in cancer. Int J Mol Sci. 20:44972019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chandan K, Gupta M and Sarwat M: Role of
host and pathogen-derived microRNAs in immune regulation during
infectious and inflammatory diseases. Front Immunol. 10:30812020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao Z, Sun W, Guo Z, Zhang J, Yu H and
Liu B: Mechanisms of lncRNA/microRNA interactions in angiogenesis.
Life Sci. 254:1169002020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mao L, Liu S, Hu L, Jia L, Wang H, Guo M,
Chen C, Liu Y and Xu L: miR-30 family: A promising regulator in
development and disease. Biomed Res Int. 2018:96234122018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tanaka T, Okada R, Hozaka Y, Wada M,
Moriya S, Satake S, Idichi T, Kurahara H, Ohtsuka T and Seki N:
Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact
of miR-30c-5p and miR-30c-2-3p regulation on oncogenic genes.
Cancers (Basel). 12:27312020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen
Y, Wang J, Liu Y, Chen P, Wu X and Wen J: Urinary microRNA-30a-5p
is a potential biomarker for ovarian serous adenocarcinoma. Oncol
Rep. 33:2915–2923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu J, Lv H, Zhang B, Xu F, Zhu H, Chen B,
Zhu C and Shen J: miR-30b-5p acts as a tumor suppressor microRNA in
esophageal squamous cell carcinoma. J Thorac Dis. 11:3015–3029.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang S, Li G, Liu C, Lu S, Jing Q, Chen
X, Zheng H, Ma H, Zhang D, Ren S, et al: miR-30e-5p represses
angiogenesis and metastasis by directly targeting AEG-1 in squamous
cell carcinoma of the head and neck. Cancer Sci. 111:356–368. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu G, Cai J, Wang L, Jiang L, Huang J, Hu
R and Ding F: MicroRNA-30e-5p suppresses non-small cell lung cancer
tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3
signaling. Exp Cell Res. 362:268–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiao H, Tian Y, Yang Y, Hu F, Xie X, Mei J
and Ding F: USP22 acts as an oncogene by regulating the stability
of cyclooxygenase-2 in non-small cell lung cancer. Biochem Biophys
Res Commun. 460:703–708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao H, Tang H, Huang Q, Qiu B, Liu X, Fan
D, Gong L, Guo H, Chen C, Lei S, et al: miR-101 targets USP22 to
inhibit the tumorigenesis of papillary thyroid carcinoma. Am J
Cancer Res. 6:2575–2586. 2016.PubMed/NCBI
|
|
45
|
Li ZH, Yu Y, DU C, Fu H, Wang J and Tian
Y: RNA interference-mediated USP22 gene silencing promotes human
brain glioma apoptosis and induces cell cycle arrest. Oncol Lett.
5:1290–1294. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang Y, Sun Q, Mu N, Sun X, Wang Y, Fan S,
Su L and Liu X: The deubiquitinase USP22 regulates PD-L1
degradation in human cancer cells. Cell Commun Signal. 18:1122020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ding F, Bao C, Tian Y, Xiao H, Wang M, Xie
X, Hu F and Mei J: USP22 promotes NSCLC tumorigenesis via MDMX
up-regulation and subsequent p53 inhibition. Int J Mol Sci.
16:307–320. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mischinger J, Comperat E, Schwentner C,
Stenzl A and Gakis G: Inflammation and cancer: What can we
therapeutically expect from checkpoint inhibitors? Curr Urol Rep.
16:592015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Thompson RH, Gillett MD, Cheville JC,
Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen
L, et al: Costimulatory B7-H1 in renal cell carcinoma patients:
Indicator of tumor aggressiveness and potential therapeutic target.
Proc Natl Acad Sci USA. 101:17174–17179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Boland JM, Kwon ED, Harrington SM,
Wampfler JA, Tang H, Yang P and Aubry MC: Tumor B7-H1 and B7-H3
expression in squamous cell carcinoma of the lung. Clin Lung
Cancer. 14:157–163. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cooper WA, Tran T, Vilain RE, Madore J,
Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan
BC, et al: PD-L1 expression is a favorable prognostic factor in
early stage non-small cell carcinoma. Lung Cancer. 89:181–188.
2015. View Article : Google Scholar : PubMed/NCBI
|
